Drug facts
MoleculeHydrochlorothiazide and Lisinopril
Generics already compete: 8 makers on the market. 24 A-rated products from 8 makers substitute at the counter.
Prinzide was first approved by the FDA on 02/16/1989 under NDA 019778; the application holder is Merck Research Laboratories Div Merck Co Inc. The Orange Book lists NDA 019778 as discontinued.
The latest NADAC for LISINOPRIL-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB is $0.04 per unit (as of 10/28/2026).
Holder Merck Research Laboratories Div Merck Co IncApplication NDA 019778Approved 02/16/1989
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Prinzide patent listed in the Orange Book Orange Book
02Competition
- Generics
- 8 generic makers Orange Book
- First generic approved
- 07/01/2002 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Hydrochlorothiazide and Lisinopril profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.04 per unitLISINOPRIL-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB, mid-priced of 3 strengths, as of 10/28/2026 CMS NADAC
- Latest recall
- 06/20/2025Class II, Lisinopril and Hydrochlorothiazide, Lupin Pharmaceuticals Inc. FDA enforcement
04Product
- Application holder
- Merck Research Laboratories Div Merck Co Inc Orange Book
- Application
- NDA 019778 Orange Book
- First approved
- 02/16/1989 Orange Book
- Dosage forms
- tablet
- Routes
- oral
- Other brand names
- Zestoretic
- Status
- NDA 019778 discontinued Orange Book
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.